Atlas Trials

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Clinical trial NCT01613846 · COMPLETED

Trial details

NCT number
NCT01613846
Sponsor
Technical University of Munich
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2012-05-01
Primary completion
2016-10-30
Enrollment
544

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.